Clinical Trial Update: Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating belinostat combined with Yttrium-90 ibritumomab tiuxetan in relapsed aggressive B-cell non-Hodgkin lymphoma has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Diffuse Large Cell Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Belinostat (belinostat)
• Yttrium-90 ibritumomab tiuxetan (yttrium-90 ibritumomab tiuxetan)

Snippet

Sponsor: University of Arizona | Conditions: Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-07-31